DIVISION OF CARDIOLOGY- SUMMARY OF WEEKLY ROUNDS
Monday, March 6 - Friday, March 10, 2017

Monday, March 6:
8:00-9:00  B6-115 UH  OTN Event #: 63452264  Cardiovascular Grand Rounds  Presenter: F. Scarth  Title of Presentation: Quality Agenda: Future Directions for QBPs and Integrated Care  Learning Objectives:
1. Provide update on Ontario’s Quality agenda.
2. Describe future direction of QBPs.
3. Communicate next steps for integrated funding models and bundled care.

12:00-1:00  B6-115 UH  OTN Event #: 64118535  Adult Congenital Cardiac Surgery Rounds  Case-based presentation and discussion  Videoconference from Toronto

Tuesday, March 7:
7:00-8:00  B6-115 UH  OTN Event #: 63493322  Complex Revascularization Rounds  Presenters: CV Surgeons & Interventionalists  Faculty Supervisors: D. Nagpal/P. Garg  Learning Objectives:
1. To develop a systematic approach to interpretation of coronary angiograms.
2. To discuss interesting case examples and their management.
3. To apply an evidence-based approach to complex revascularization cases in order to improve outcomes.

2:00-5:00  B6-128 UH  ACADEMIC HALF DAY/DIDACTIC EDUCATION SESSIONS:
2:00-3:00  B6-128 UH  The heart and systemic disease: hemochromatosis, amyloidosis & sarcoidosis  Presenter: B. Al-Sabeq  Faculty Supervisor: G. Wisenberg  Learning Objectives:
1. Review the clinical manifestations, diagnosis and management of cardiac sarcoaidosis.
2. Review the clinical manifestations, diagnosis and management of cardiac hemochromatosis.
3. Review the clinical manifestations, diagnosis and management of cardiac amyloidosis.

3:00-4:00  Nuclear Rounds  Presenter: C. Akincioglu

4:30-5:30  Clinical Cardiology Rounds  Presenter: A. Sachedina  Faculty Supervisor: R. Bagur  Title of Presentation: Acby Breaky Heart  Learning Objectives:
1. To assess an unusual case of cardiomyopathy.
2. To review the suspected pathophysiology of the unusual case of cardiomyopathy.
3. To discuss the management of the unusual case of cardiomyopathy.

Wednesday, March 8:
8:00-9:00  B6-115 UH  OTN Event #: 63526882  EP Rounds: Research Rounds  Presenters: Attendings & Fellows  Learning Objectives:
1. To review current and active EP research protocols at LHSC.
2. To summarize the findings of current EP research projects at LHSC.
3. To discuss new related research hypotheses and potential projects.

12:00-1:00  Adult Congenital Cardiac Teaching Rounds  Videoconference from Toronto  Rounds cancelled - to resume March 22, 2017

Thursday, March 9:
8:00-9:00  B6-128 UH  Graphics Rounds: Ventricular hypertrophy/ enlargement  Presenter: J. Brown

5:30 pm  The Springs Restaurant, 310 Springbank Drive, London. 519.657.1100  Sponsor: Novartis Pharmaceuticals Canada Inc.  Journal Club  Attendance open to Residents, Fellows and Division Members. RSVP to Charlene Grass (Ext 33830 or email charlene.grass@lhsc.on.ca)  Presenter: K. Sidhu  Faculty Supervisor: P. Diamantouros  Paper for Presentation: Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy  A. Di Marco, MD, et al.  Cardiol HF 2017;5:28-38  Learning Objectives:
1. Review the existing evidence for ICDs in DCM.
2. Review the role of LGE in risk stratification to date.
3. Discuss the current meta-analysis.

Friday, March 10:
8:00-9:00  B6-115 UH  EP Rounds: Tracing Rounds  Presenters: Attendings & Fellows  Learning Objectives:
1. To develop a systematic approach to EP tracings.
2. To discuss interesting case examples.
3. To review electrophysiology principles and concepts.

Some of these educational activities/rounds are an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, approved by the Division of Cardiology Education Committee - Western University.

Supported by unrestricted grants-in-aid provided by:
- Aegerion Pharmaceuticals (Juxtapid (lomitapide)), Amgen Canada Inc. (Repatha), AstraZeneca Canada Inc. (Bilinta (Ticagrelor)), Bayer Inc. (XARELTO® rivaroxaban tablel), Bristol-Myers Squibb Canada & Pfizer Canada Inc., (Elquis (apixaban)), Medtronic of Canada Inc., Merck (Januvia, Janumet), Novartis Pharmaceuticals Canada Inc. (Entresto), Sanofi (Plavix), Servier Canada Inc. (Coverysyl, Coversyly Plus, Viaxoram, Lixiana)